Protandim Dietary Supplement to Be Released in February 2005

DENVER, Nov 19, 2004 (BUSINESS WIRE) -- Lifeline Therapeutics, Inc. (LFLT) announced today that Protandim, a scientifically-based anti-aging dietary supplement is scheduled to be released in February 2005.

Protandim is not an antioxidant, but its patent-pending formulation induces the body to produce more of its own natural antioxidant enzymes, thereby utilizing biology not chemistry to fight oxidation.

The body's primary antioxidant is Superoxide Dismutase (SOD) and its levels have previously been shown to be directly correlated to aging in 14 different species, including humans. Species with the highest amounts of SOD live the longest and any increase in SOD corresponds to an increase in lifespan. According to separate studies conducted by John Tower, a molecular biologist at the University of Southern California, and by molecular biologist John Phillips of the University of Guelph in Ontario, the extended time of life was youth. Old age was postponed.

SOD was discovered by Dr. Joe McCord and his associate in 1969, for which they received the prestigious Elliot Cresson medal, previously awarded to Henry Ford, the Wright brothers, Madam Curie and other notable figures that have made great advances for humanity. Since Dr. McCord's discovery, there have been approximately 25,000 scientific studies and/or articles about SOD, thereby confirming its importance within the scientific community. Dr. McCord now serves as LFLT's Director of Science.

Protandim will initially be sold directly by LFLT through an undated Website (currently under development) and call center operations. The company plans to evaluate and consider distribution alternatives for additional countries and also consider other possible channels of distribution. These other channels of distribution may also include a health practitioner distribution system.

After very promising pre-clinical results, Protandim is currently undergoing human trials at the renowned Webb-Waring Institute of Cancer, Aging and Antioxidant Research (Webb-Waring). Although the duration of the studies will continue for a period that extends past the projected product release timeframe, there is already enough data to demonstrate the safety and efficacy of the Protandim product.


It has been thought that antioxidants, such as vitamins C and E and many other antioxidants found in fresh fruits and vegetables, serve to limit oxidative stress (as measured by lipid peroxidation) in vivo. However, recent studies have shown that supplemental vitamins produced no effect on biomarkers of lipid peroxidation in healthy men with low fruit and vegetable intake (whether smokers or non-smokers). LFLT believes that Protandim offers a better approach - to upregulate the body's natural family of antioxidant enzymes: Superoxide Dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GPX). Protandim allows these enzymes to be produced where they are most needed - within the cells where oxidative stress actually occurs. This is in stark contrast to traditional antioxidant supplements, which have to pass significant digestive and absorption barriers and simply can't be consumed in the quantities needed to protect the body against the damage caused by oxidative stress. Not hampered by quantity, digestive and absorption constraints, Protandim acts as a catalyst to cause the body to increase the production of its own antioxidant defense system.


Lifeline Therapeutics, Inc. is a publicly-traded (LFLT) company based in Denver, Colorado, that is dedicated to the manufacture, marketing and distribution of therapies that promote "Healthy Life Expectancy." LFLT is initially focusing exclusively on unique antioxidant products under its Protandim brand. LFLT's business plan incorporates an array of product candidates for nutraceutical, pharmaceutical and cosmeceutical applications. These therapies center on the body's primary defense mechanism against oxidative stress - the co-regulation of the natural antioxidant enzymes, Superoxide Dismutase (SOD), Catalase (CAT), and Glutathione Peroxidase (GPX).

For more information, please contact Bill Driscoll at [email protected]

The latest news updates are available at

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences include the Company's limited cash flow and the rapid development of technology, lack of liquidity for the Company's common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.